Clinical Data

UriVarx™ was evaluated in two clinical studies. The first study compared the efficacy of crateva, horsetail and mineral combination compared to UriVarx™. Comparison was made using the percent (%) reduction in frequency and urination and nocturia for each of the treatment groups at months one and three. Following one month of use, UriVarx™ was more effective in reducing the frequency of day urination (Figure 1) and superior in reducing nocturnia (Figure 2) compared to crateva and horsetail alone.

Day Frequency % Reduction from Baseline   Nocturia % Reduction from Baseline    

UriVarx™ was evaluated in an 8-week, double-blind, randomized, placebo-controlled, clinical study conducted at two sites. UriVarx™ was assessed in 142 subjects (81 female and 61 male) on urinary frequency and urgency. Data was collected at 2, 4, and 8 weeks. The primary outcome measure was self-reported urinary frequency defined as the number of voluntary diurnal and/ or nocturnal micturitions. Baseline reported measurements were similar between groups. At week 8, mean (n/day) urinary day frequency was significantly lower in subjects administered UriVarx™ compared to placebo (Figure 3). Similarly, mean episodes of nocturia and urgency were significantly fewer versus placebo (Figures 4 & 5). Significant improvements in quality of life were reported at end of study in comparison to placebo.*

Day Frequency   Nocturia   Urgency

There were no adverse events leading to discontinuation. Five episodes of transient adverse reactions were reported in the UriVarx™ group which included diarrhea (2.9%), UTI (2.9%) and flatulence (1.5%).

For more information, please read the articles below:


*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

In clinical trials, UriVarx™ has been used safely with minor side effects for up to 8 weeks. There were no adverse events leading to discontinuation. Five episodes of transient adverse reactions were reported in the UriVarx™ group which included diarrhea (2.9%), UTI (2.9%) and flatulence (1.5%). Pregnant women and women who are nursing should not take supplements without first talking to their doctor.

SUGGESTED USE: As a dietary supplement, start with one capsules a day in the morning with a meal or as directed by your healthcare practitioner. IF well tolerated you may increase to two capsules a day.
WARNINGS: Not for use in persons under the age of 18. Ask your doctor before using UriVarx™. Do not use if allergic to any ingredient in UriVarx™. Stop using if you experience any side effect.
CAUTION: Keep tightly closed in a cool dry place at controlled room temperature of 15°-30°C (59°-86°F). DO NOT USE if inner seal or outer neck band is broken. Keep out of the reach of children.